Plant Name: Rheum undulatum
Taxonomic Information:
Plant ID: NPO88
Plant Latin Name: Rheum undulatum
Taxonomy Genus: Rheum
Taxonomy Family: Polygonaceae
Plant External Links:
NCBI TaxonomyDB:
137227
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Korea; IndiaTraditional Medicine System:
Indian Folk; AyurvedaGeographical Distribution:
South Korea; India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HDAC2; HDAC8; | |
| TDP1; PIK3CB; PIK3CA; GFER; HSD17B10; NQO2; | |
| CA12; CA9; CA14; | |
| ESR1; | |
| PTGS2; | |
| KDM4E; | |
| FUT7; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Histone deacetylase | HDAC2 | Histone deacetylase 2 | Q92769 | CHEMBL1937 |
| Histone deacetylase | HDAC8 | Histone deacetylase 8 | Q9BY41 | CHEMBL3192 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.644E-07 | 2.645E-03 | CA12, CA14, CA9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.665E-07 | 3.338E-03 | CYP1A1, CYP1B1, ESR1, HDAC2, HDAC8, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.012E-06 | 3.671E-03 | CYP1A1, CYP1B1, CYP3A4, GFER, HSD17B10, KDM4E, NQO2, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.411E-06 | 4.390E-03 | CYP1A1, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.748E-06 | 6.650E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.165E-06 | 7.558E-03 | CYP1A1, CYP1B1, CYP3A4, NQO2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.706E-07 | 5.193E-05 | CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 4.167E-06 | 1.486E-04 | HDAC2, PIK3CA, PIK3CB, ESR1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.901E-07 | 5.193E-05 | CA12, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.385E-05 | 3.705E-04 | CYP1A1, CYP1B1, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.952E-05 | 3.862E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.526E-05 | 3.862E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.920E-05 | 3.865E-04 | HDAC2, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 3.682E-05 | 3.865E-04 | HDAC2, PIK3CA, PIK3CB, HDAC8 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.170E-05 | 3.862E-04 | CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.159E-05 | 3.865E-04 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 4.335E-05 | 3.865E-04 | HDAC2, PIK3CA, PIK3CB |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.335E-05 | 3.865E-04 | CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 7.077E-05 | 5.825E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.076E-04 | 8.225E-04 | PIK3CA, PIK3CB, ESR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.471E-04 | 1.049E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.996E-04 | 2.004E-03 | PIK3CA, LMNA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.679E-04 | 2.782E-03 | HDAC2, PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 4.271E-04 | 2.688E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 8.855E-04 | 4.120E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.730E-04 | 4.120E-03 | HDAC2, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.277E-03 | 5.242E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 6.204E-04 | 3.492E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.527E-04 | 3.492E-03 | CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.102E-03 | 4.717E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.323E-03 | 5.242E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 8.261E-04 | 4.120E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.465E-03 | 5.597E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 9.397E-04 | 4.189E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.716E-03 | 5.735E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.563E-03 | 5.735E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.634E-03 | 7.045E-03 | PIK3CA, CYP1B1, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.769E-03 | 5.735E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 1.876E-03 | 5.736E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.716E-03 | 5.735E-03 | CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.769E-03 | 5.735E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.043E-03 | 5.909E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.822E-03 | 5.735E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.159E-03 | 6.078E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.187E-03 | 8.120E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 3.048E-03 | 7.956E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.849E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 3.548E-03 | 8.627E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 3.474E-03 | 8.627E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.083E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 3.849E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 2.460E-03 | 6.748E-03 | PIK3CA, PIK3CB |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.067E-03 | 9.512E-03 | FUT7, CYP1A1, PTGS2, CYP3A4, HSD17B10 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04070 | Phosphatidylinositol signaling system | 3.849E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 4.083E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 4.004E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.242E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 4.908E-03 | 9.377E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 4.486E-03 | 8.890E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 4.323E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 4.323E-03 | 8.727E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 4.737E-03 | 9.216E-03 | PIK3CA, PIK3CB |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | HDAC2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; PTGS2; PIK3CB; NQO2; HDAC8; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; CA9; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
